BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET
09 June 2021 - 10:05PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)
(TSX-V:BCT) (“BriaCell” or the “Company”), a
clinical-stage biotechnology company specializing in targeted
immunotherapies for advanced breast cancer, announces that CEO Dr.
William V. Williams will host a corporate and clinical update call
on Wednesday, June 16, 2021 at 4:30 p.m. ET.
Participants are asked to pre-register for the
call through the following link:
https://dpregister.com/sreg/10157385/e952dabc3b.
Please note that registered participants will
receive their dial in number upon registration and will dial
directly into the call without delay. Those without Internet access
or unable to pre-register may dial in by calling: 1-866-777-2509
(U.S. domestic), 1-412-317-5413 (international). All callers should
dial in approximately 10 minutes prior to the scheduled start time
and ask to be joined into the BriaCell Therapeutics call.
The conference call will also be available
through a live webcast found here.
A telephonic replay of the call will be
available through June 30, 2021 and may be accessed by calling
1-877-344-7529 (U.S. domestic) or 1-412-317-0088 (international) or
855-669-9658 (Canada) and using access code 10157385.
Although there will be no live Q&A session,
management will address pre-submitted questions during the call.
Those wishing to submit a question may do so via
investors@briacell.com using the subject line “Conference Call
Question Submission.” All questions must be submitted by
Friday, June 11, 2021 by 5:00 p.m. ET.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer. For additional information on
BriaCell, please visit: https://briacell.com/.
Forward Looking Statements
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading "Risks and Uncertainties" in the
Company's most recent Management’s Discussion and Analysis, under
“Risks and Uncertainties” and in the Company's other filings with
the Canadian securities regulatory authorities and the U.S.
Securities and Exchange Commission, all of which are available
under our profiles on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained in this
announcement are made as of this date, and BriaCell Therapeutics
Corp. undertakes no duty to update such information except as
required under applicable law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
Company Contact:William V. Williams,
MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamDirector of Public
RelationsCORE IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024